Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00125
|
|||||
| Drug Name |
Levodopa
|
|||||
| Synonyms |
Levodopa (optimized formulation, Parkinson's disease); Levodopa (optimized formulation, Parkinson's disease), Orion; More effective levodopa (Parkinson's disease), Orion
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Parkinson's Disease [ICD11:8A00.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H11NO4
|
|||||
| Canonical SMILES |
C1=CC(=C(C=C1CC(C(=O)O)N)O)O
|
|||||
| InChI |
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
|
|||||
| InChIKey |
WTDRDQBEARUVNC-LURJTMIESA-N
|
|||||
| CAS Number |
CAS 59-92-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 197.19 | Topological Polar Surface Area | 104 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321285
,11111115
,11112155
,11335627
,11360866
,11363348
,11365910
,11368472
,11374316
,11376634
,11461838
,11466045
,11467165
,11484127
,11485710
,11488312
,11492354
,11494268
,11532916
,11537951
,15120911
,15219946
,17405017
,222573
,24277914
,24863554
,26613179
,26679497
,26719283
,26746620
,26753566
,29225059
,3136680
,3648
,46508120
,47216726
,47291084
,47440197
,47440198
,47736420
,47810699
,47959681
,555833
,7847127
,7886892
,7979689
,8001566
,8143351
,8150164
,8153771
|
|||||
| ChEBI ID |
ChEBI:15765
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | LAT1 | Transporter Info | L-type amino acid transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | LAT1 | Transporter Info | Km =200 microM | Human embryonic kidney cells (HEK293)-LAT1 | [2] | |
| References | ||||||
| 1 | Levodopa was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017 Mar 8;7:43580. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.